Superior Vena Cava Obstruction (SVCO)

Superior vena cava obstruction (SVCO) causes progressive facial oedema, arm oedema, JVD, and dyspnoea, with a positive Pemberton's sign (facial flushing/cyanosis on arm elevation). The commonest malignant cause is SCLC, followed by lymphoma and…

UKONS / NICE SVCO Guidance

The pathway

1 · Recognise and assess severity

Facial oedema (worse lying flat or bending forward)
Arm oedema and JVD
Pemberton's sign: ask patient to raise both arms — positive if face flushes or becomes cyanotic
Stridor or reduced GCS → emergency intervention
Assess dyspnoea severity and SpO₂

2 · Imaging and tissue diagnosis

CT chest with IV contrast: confirms SVC obstruction, extent, and identifies primary cause
CXR may show mediastinal widening or right hilar mass
Obtain tissue biopsy if cause unknown — CT-guided percutaneous or bronchoscopy
Do not delay stenting for biopsy in emergency presentations

3 · Dexamethasone

Dexamethasone 8mg BD PO or IV
Reduces peri-tumoural oedema — symptom improvement within 24–48 hours
Start immediately on clinical diagnosis
Add omeprazole 20mg OD for gastric protection

4 · SVC stenting for urgent/emergency cases

Endovascular SVC stenting is the fastest way to relieve obstruction (relief within 24–72h)
Indicated for severe or rapidly progressive symptoms, stridor, or haemodynamic compromise
Interventional radiology via femoral or subclavian approach
Effective regardless of histology — does not preclude subsequent chemotherapy or radiotherapy

5 · Chemotherapy for chemo-sensitive tumours

SCLC: platinum-based chemotherapy — high response rate; may be first-line if tissue confirmed
Lymphoma: R-CHOP or equivalent — chemotherapy is first-line
Liaise with oncology team — do not delay stenting for chemotherapy in emergency

6 · Radiotherapy

NSCLC or tumours not amenable to chemotherapy: palliative radiotherapy to mediastinum
Emergency radiotherapy if stenting unavailable
Slower onset than stenting — response over days to weeks

7 · Anticoagulation for thrombotic cause

Central line thrombus: therapeutic LMWH (enoxaparin 1.5mg/kg OD SC)
Consider central line removal if thrombus is line-related and alternative access available
Tumour-related: anticoagulation adjunct to stent/oncological treatment

Drugs

Drug	Dose	Route	Notes
Dexamethasone	8mg BD	PO or IV	Start immediately. Reduces peri-tumoural oedema. Add omeprazole cover. Taper once definitive treatment initiated.
Omeprazole	20mg OD	PO	Gastric protection during dexamethasone course.
Enoxaparin	1.5mg/kg OD	SC	Thrombotic SVCO or central line thrombus. Preferred over DOAC in active malignancy.
Furosemide	40mg	PO or IV	For symptomatic oedema if volume overloaded. Use cautiously — venous return is obstructed in SVCO.

When to escalate

Stridor or airway compromise — emergency SVC stenting or radiotherapy; anaesthetics for airway assessment,Reduced GCS or haemodynamic compromise — ICU, emergency stenting,Unknown primary — urgent tissue biopsy before chemotherapy unless life-threatening urgency,SCLC or lymphoma confirmed — urgent oncology referral for chemotherapy alongside stenting,Central line thrombus causing SVCO — haematology referral, consider line removal and therapeutic anticoagulation

Reference: UKONS / NICE Oncological Emergencies Guidance / ESMO SVCO Clinical Practice Guidelines 2021

This page is the reference half

The app adds what a web page cannot: a VINDICATE differential builder, worked on-call scenarios with full A–E findings, recall practice, and all of it offline.